Answer
Delstrigo is indicated to treat HIV-1 infection in adults without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir.
Sources for this answer
- Delstrigo 100 mg /300 mg /245 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked